A novel beta coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has been identified as the causative pathogen for the present pandemic. The objective of the study was to measure the levels of IgG antibodies targeting the SARS-CoV-2 during the peak period of the COVID-19 pandemic in Odisha State, India to know the magnitude of SARS-CoV-2 exposure, the prevalence of herd immunity in the population, the distribution of IgG-positive cases examined according to ABO blood groups and the number of blood donors with higher neutralizing IgG antibody titre who later on were converted into Plasma Donors donating Convalescent Plasma (CP).

This observational prospective study was conducted for a duration of three months on 1032 number of Blood donors consisting of 1025 number of males and 07 number of females. The samples of donors were subjected to Electro- chemiluminescence immunoassay (ECLIA) to detect SARS-CoV-2 IgG antibodies.

Out of 1032 Donors, 370(35.9%) were SARS-COV-2 IgG positive which included 303 donors (29.36%) with neutralizing antibody titre of SARS-COV2 IgG antibodies above 1:80. SARS-COV-2 IgG positive cases consisted of 367(35.8%) male and 3(42.9%) female donors. The number of IgG positive cases were highest in 21–40 years’ age group i.e. 323 out of 869(37.2%). In terms of Blood group, 145(42.4%) out of 342 were from B RhD positive group. Out of 22 donors who were positive with COVID 19 in the past with neutralizing IgG antibody titre more than 1:80, 6(27.3%) persons came for voluntary convalescent plasma(CP) donation.

A high prevalence of SARS-CoV-2 antibodies was detected among blood donors which indicated a high level of exposure to the virus within the population and development of innate immunity against the virus. Policy makers can add the protocol of antibody testing in the screening of blood donors to enhance the number of Plasma Donation cases for the treatment of serious COVID patients.